Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VRAX vs AKAN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AKAN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–3 Matrix Metrics)

AKAN Overall Winner 6-Pillar Tally: VRAX 2 – 3 AKAN (1 Tie) Matrix Metrics: VRAX 3 – 4 AKAN

As of Nov 20, 2026, Akanda Corp. Common Shares (AKAN) is the stronger overall head-to-head candidate over Virax Biolabs Group Limited (VRAX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VRAX carries a Unified Composite Score of 46.5/100 (HOLD) at $0.33 (N/M Forward P/E, -51515.2% operating margin), whereas AKAN carries 39.8/100 (SELL) at $4.23 (N/M Forward P/E, -1254.5% operating margin).

  • Composite vs. Pillar Nuance: While VRAX currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. AKAN 39.8/100 SELL), AKAN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-1254.5% vs. -51515.2% operating margin) and revenue trajectory (+21.9% vs. +684.9% YoY).
  • Technical & Structure Timing Caution: VRAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.3); meanwhile AKAN is in a Breakdown options structure phase (RSI 75.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VRAX vs AKAN
VRAX NASDAQ
Virax Biolabs Group Limited Ordinary Shares
In Vitro & In Vivo Diagnostic Substances
$0.33
-12.89% 1D
Market Cap $470,745
TTM Revenue $12,423
Forward P/E N/M
Beta / 30D Vol -8.20β · 162% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 45.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.8%), weak momentum, RSI 17
RSI-14: 17.3 · SMA20: $0.84 · SMA50: $1.56
AKAN NASDAQ Head-to-Head Winner
Akanda Corp. Common Shares
Medicinal Chemicals & Botanical Products
$4.23
+23.32% 1D
Market Cap $12.2M
TTM Revenue $662,469
Forward P/E N/M
Beta / 30D Vol 4.82β · 524% Vol
Unified Composite Score
39.8 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.2 · SMA20: $1.52 · SMA50: $1.88

6-Pillar Scorecard Institutional Category Breakdown (VRAX 2 – 3 AKAN)

Columns: Metric · VRAX · AKAN
1. Valuation Multiples AKAN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 37.9x 18.5x
2. Growth & Scale VRAX
Revenue Growth (YoY) +684.9% +21.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $12,423 $662,469
Market Cap $470,745 $12.2M
3. Profitability & Quality AKAN
Gross Margin 61.9% -12.0%
Operating Margin -51515.2% -1254.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -78.6% -60.9%
4. Balance Sheet & Cash Flow AKAN
Cash Generation (TTM) -$6.0M EBITDA -$7.9M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $13.08 Book/Sh · -78.6% ROE -60.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VRAX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VRAX (3) vs AKAN (4)
Institutional Metric VRAX AKAN Criterion Row Edge
Market Capitalization
Scale
$470,745 $12.2M Larger Scale AKAN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+684.9% +21.9% Higher Growth VRAX
Operating Margin (TTM)
Profitability
-51515.2% -1254.5% Higher Margin AKAN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-78.6% -60.9% Higher ROE AKAN
52-Week Range Position
Momentum
2% ($0–$13) 5% ($0–$79) Stronger Trend AKAN
Beta / 30D Volatility
Risk Regime
-8.20β · 162% Vol 4.82β · 524% Vol Lower Realized Risk VRAX
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 39.8 / 100 (SELL) Higher Composite VRAX
Trailing 12M Revenue (USD)
Operating Scale
$12,423 $662,469 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% -12.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 37.9x EV/Rev N/M PEG · 18.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.0M EBITDA ($13.08 Book/Sh · -78.6% ROE) -$7.9M EBITDA (-60.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AKAN +340.96 pp
VRAX: -73.13% · AKAN: +267.83%
3M Horizon AKAN +103.11 pp
VRAX: -88.94% · AKAN: +14.17%
6M Horizon VRAX +104.0 pp
VRAX: +19.6% · AKAN: -84.4%
1Y Horizon AKAN +382.91 pp
VRAX: -24.62% · AKAN: +358.29%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRAX vs AKAN. Trailing 12-month operating profitability (VRAX -51515.2% vs AKAN -1254.5%) and valuation multiples (VRAX N/M vs AKAN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VRAX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$12,423
Gross Margin61.9%
Op. Margin-51515.2%
ROE / Fwd P/E-78.6% · N/M
AKAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$662,469
Gross Margin-12.0%
Op. Margin-1254.5%
ROE / Fwd P/E-60.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VRAX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VRAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKAN BREAKDOWN
140d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact AKAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VRAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $470,745 market capitalization and -51515.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AKAN Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $12.2M market capitalization and -1254.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VRAX vs AKAN Key Questions & Quantitative Answers

As of Nov 20, 2026, Akanda Corp. Common Shares (AKAN) is the stronger overall head-to-head candidate over Virax Biolabs Group Limited (VRAX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VRAX carries a Unified Composite Score of 46.5/100 (HOLD) at $0.33 (N/M Forward P/E, -51515.2% operating margin), whereas AKAN carries 39.8/100 (SELL) at $4.23 (N/M Forward P/E, -1254.5% operating margin). Composite vs. Pillar Nuance: While VRAX currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. AKAN 39.8/100 SELL), AKAN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-1254.5% vs. -51515.2% operating margin) and revenue trajectory (+21.9% vs. +684.9% YoY). Technical & Structure Timing Caution: VRAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.3); meanwhile AKAN is in a Breakdown options structure phase (RSI 75.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VRAX leads the Growth & Scale pillar: VRAX posts +684.9% YoY revenue growth and +0.0% YoY earnings growth on $12,423 TTM revenue (61.9% gross margin, -51515.2% operating margin), compared with AKAN at +21.9% YoY revenue growth and +0.0% YoY earnings growth on $662,469 TTM revenue (-12.0% gross margin, -1254.5% operating margin). On trailing 12-month operating scale, VRAX generates $12,423 in USD-normalized revenue versus $662,469 for AKAN. In operating R&D and SG&A reinvestment, VRAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKAN.

AKAN screens cheaper on headline valuation multiples. VRAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.9x EV/Revenue (unreported EBITDA margin), whereas AKAN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRAX (-78.6% ROE) versus AKAN (-60.9% ROE) capital efficiency.

In options market volatility and institutional positioning, VRAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-8.20β · 162% Vol realized risk). By comparison, AKAN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (4.82β · 524% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.